Collaboration to focus on the continued development of chronic heart failure treatment SERCA2a activator compounds adding to Windtree’s acute treatment Istaroxime WARRINGTON, Pa., March 22, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today […]
Tag: Windtree
Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device
New patent covers updated aerosol delivery system and design until 2039 WARRINGTON, Pa., Feb. 16, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that the United States Patent and Trademark Office (USPTO) […]
Windtree Strengthens Its Board by Appointing Three New Directors
Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience WARRINGTON, Pa., Feb. 4, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today […]
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development
WARRINGTON, Pa., Feb. 1, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Joseph Soffer, M.D., F.A.C.C., as Executive Director of Clinical Development, effective immediately. “We are thrilled to welcome Joe […]
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
Study Opens a New, Additional Area of Development for Istaroxime WARRINGTON, Pa., Oct. 1, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 […]
Windtree Therapeutics Reports Second Quarter 2020 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today reported financial results for the second quarter ended June 30, 2020 and provided […]
Windtree Appoints John Hamill as Chief Financial Officer
WARRINGTON, Pa., July 20, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced John Hamill has been appointed Senior Vice President, Chief Financial Officer. In this role, Mr. Hamill will […]
Windtree Announces Initial European Trial Sites Activated in AEROSURF® Bridging Study and a Collaboration for a Concomitant Independent Cerebral Physiology Study
WARRINGTON, Pa., June 24, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that all initial European trial sites are active and enrolling or able to enroll patients into […]
Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market
WARRINGTON, Pa., May 20, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per […]
Windtree Therapeutics Announces Reverse Stock Split
WARRINGTON, Pa., April 28, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced a 1-for-3 reverse stock split of its issued and outstanding common stock. The Company’s common stock will […]
Recent
Popular
- No commented posts yet